Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $1.1 million.

  • OptimizeRx's Depreciation & Amortization (CF) fell 136.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 235.74%. This contributed to the annual value of $4.3 million for FY2024, which is 8022.48% up from last year.
  • Per OptimizeRx's latest filing, its Depreciation & Amortization (CF) stood at $1.1 million for Q3 2025, which was down 136.99% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q3 2024 and a low of $385152.0 during Q4 2021
  • Over the past 5 years, OptimizeRx's median Depreciation & Amortization (CF) value was $578116.0 (recorded in 2022), while the average stood at $759600.9.
  • As far as peak fluctuations go, OptimizeRx's Depreciation & Amortization (CF) tumbled by 1956.63% in 2023, and later soared by 13447.54% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Depreciation & Amortization (CF) stood at $385152.0 in 2021, then grew by 18.54% to $456545.0 in 2022, then surged by 120.57% to $1.0 million in 2023, then rose by 8.64% to $1.1 million in 2024, then decreased by 1.28% to $1.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.1 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.1 million in Q1 2025.